NYU Psilocybin Cancer Anxiety Study May Help Change Schedule I Status

NYU is conducting a study, supporting earlier UCLA and Hopkins studies, that even a single does of psilocybin, a psychoactive compound found in magic mushrooms, had decreased cancer-related anxiety and increased patients’ sense of well-being, even 14 months after they’d taken it. The NYU Psilocybin Cancer Anxiety Study should be published in about a year, and may lead to a Phase III drug trial, & ultimate removal of psilocybin from Schedule I.